Aurobindo Pharma Limited (AUROPHARMA)

1,319.45

INR
-29.35(-2.18%)
As of January 3, 2025 10:00:00 AM

About Aurobindo Pharma Limited

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
2.40
Operating MarginLast 12 months
15.19
+8% quarterly YoY
Market Cap
72606.06 CrINR
Employees
26015
CEO
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
Website

Aurobindo Pharma Limited (AUROPHARMA)

1,319.45

INR
-29.35(-2.18%)
As of January 3, 2025 10:00:00 AM

About Aurobindo Pharma Limited

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
2.40
Operating MarginLast 12 months
15.19
+8% quarterly YoY
Market Cap
72606.06 CrINR
Employees
26015
CEO
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
Website